Bilaketaren emaitzak - Helmout Modjtahedi

  • Erakusten 1 - 8 emaitzak -- 8
Findu emaitzak
  1. 1
    Therapeutic application of monoclonal antibodies in cancer: advances and challenges

    Therapeutic application of monoclonal antibodies in cancer: advances and challenges nork Helmout Modjtahedi, S. Ali, Sharadah Essapen

    Argitaratua 2012
    Testu osoa
    Revisão
    Gogokoenen artean sartu
    Gorde:
  2. 2
    A comprehensive review of the preclinical efficacy profile of the ErbB family blocker afatinib in cancer

    A comprehensive review of the preclinical efficacy profile of the ErbB family blocker afatinib in cancer nork Helmout Modjtahedi, Byoung Chul Cho, Martin C. Michel, Flavio Solca

    Argitaratua 2014
    Testu osoa Testu osoa
    Revisão
    Gogokoenen artean sartu
    Gorde:
  3. 3
    Synergistic effects of various Her inhibitors in combination with IGF-1R, C-MET and Src targeting agents in breast cancer cell lines

    Synergistic effects of various Her inhibitors in combination with IGF-1R, C-MET and Src targeting agents in breast cancer cell lines nork Aryan Stanley, G. Hossein Ashrafi, Alan M. Seddon, Helmout Modjtahedi

    Argitaratua 2017
    Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  4. 4
    Treatment with a combination of the ErbB (HER) family blocker afatinib and the IGF-IR inhibitor, NVP-AEW541 induces synergistic growth inhibition of human pancreatic cancer cells

    Treatment with a combination of the ErbB (HER) family blocker afatinib and the IGF-IR inhibitor, NVP-AEW541 induces synergistic growth inhibition of human pancreatic cancer cells nork Nikolaos Ioannou, Alan M. Seddon, Angus Dalgleish, David Mackintosh, Helmout Modjtahedi

    Argitaratua 2013
    Testu osoa Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  5. 5
    Overexpression of epidermal growth factor receptor in human head and neck squamous carcinoma cell lines correlates with matrix metalloproteinase-9 expression andin vitro invasion

    Overexpression of epidermal growth factor receptor in human head and neck squamous carcinoma cell lines correlates with matrix metalloproteinase-9 expression andin vitro invasion nork Pornchai O‐charoenrat, Peter Rhŷs‐Evans, Helmout Modjtahedi, William Court, Gary Box, Suzanne A. Eccles

    Argitaratua 2000
    Testu osoa Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  6. 6
    Anti-tumour activity of afatinib, an irreversible ErbB family blocker, in human pancreatic tumour cells

    Anti-tumour activity of afatinib, an irreversible ErbB family blocker, in human pancreatic tumour cells nork Nikolaos Ioannou, Angus Dalgleish, Alan M. Seddon, David Mackintosh, Ulrich Guertler, Flavio Solca, Helmout Modjtahedi

    Argitaratua 2011
    Testu osoa Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  7. 7
    Development and Characterization of Three Novel FGFR Inhibitor Resistant Cervical Cancer Cell Lines to Help Drive Cervical Cancer Research

    Development and Characterization of Three Novel FGFR Inhibitor Resistant Cervical Cancer Cell Lines to Help Drive Cervical Cancer Research nork Nauf Bou Antoun, Hiba-Tun-Noor A. Mahmood, Anthony J. Walker, Helmout Modjtahedi, Richard Grose, Athina‐Myrto Chioni

    Argitaratua 2025
    Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  8. 8
    Phase I trial and tumour localisation of the anti-EGFR monoclonal antibody ICR62 in head and neck or lung cancer

    Phase I trial and tumour localisation of the anti-EGFR monoclonal antibody ICR62 in head and neck or lung cancer nork Helmout Modjtahedi, Tamas Hickish, Margery Nicolson, J. Moore, JM Styles, S. A. Eccles, Elise Jackson, Janine Salter, John Sloane, M. Loreto Spencer, K. Priest, Isabel Smith Zubiaga, Christopher Dean, M. Gore

    Argitaratua 1996
    Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:

Bilaketa egiteko lanabesak: